Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery? (Q92927460)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

title

Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Angela De Simone

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

publication date

2 May 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

1067-1073

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain

2 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Global epigenomic reconfiguration during mammalian brain development

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

The emerging field of epigenetics in neurodegeneration and neuroprotection

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

An epigenetic blockade of cognitive functions in the neurodegenerating brain

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Prospects for the development of epigenetic drugs for CNS conditions

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

A perspective on multi-target drug discovery and design for complex diseases

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC6 is a microtubule-associated deacetylase

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Class IIa HDACs - new insights into their functions in physiology and pathology

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC2 negatively regulates memory formation and synaptic plasticity.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

The specific role of histone deacetylase 2 in adult neurogenesis.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Complex neuroprotective and neurotoxic effects of histone deacetylases.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Selective Toxicity by HDAC3 in Neurons: Regulation by Akt and GSK3β

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Inhibition of Histone Deacetylase 3 Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Acetylation: a new key to unlock tau's role in neurodegeneration

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Histone deacetylase 6 interacts with the microtubule-associated protein tau

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Loss of HDAC5 impairs memory function: implications for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Recovery of learning and memory is associated with chromatin remodelling

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Dual or multi-targeting inhibitors: The next generation anticancer agents

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Inside HDAC with HDAC inhibitors

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Phosphodiesterases as therapeutic targets for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Oxidative stress in Alzheimer's disease: are we connecting the dots?

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Cinnamoyl inhibitors of tissue transglutaminase.

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

HDAC6 regulates mitochondrial transport in hippocampal neurons

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Designed multiple ligands. An emerging drug discovery paradigm

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Epigenetic-based therapy: From single- to multi-target approaches

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Zinc binding groups for histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Selecting Good 'Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Designing multiple ligands - medicinal chemistry strategies and challenges

1 reference

https://api.crossref.org/works/10.1002/CMDC.201900174

7 January 2021

Identifiers

DOI

10.1002/CMDC.201900174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30958639 AND SRC:MED&resulttype=core&format=json

2 May 2020

1 reference